The temporal progression of lung immune remodeling during breast cancer metastasis
Cancer Cell · 2024-06 · 42 (6) · 1018-1031.e6
DOI: 10.1016/j.ccell.2024.05.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Cell, 2024-06. Verfasst von Christopher S McGinnis und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Stanford University, Stanford, CA 94305, USA; Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA 94158, USA; …. Hauptthemen laut MEDLINE: Lung Neoplasms, Breast Neoplasms, Killer Cells, Natural, Tumor Microenvironment. Die Arbeit wurde bisher 76-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Congressionally Directed Medical Research Programs, Parker Institute for Cancer Immunotherapy.
Abstract (Originalsprache)
Tumor metastasis requires systemic remodeling of distant organ microenvironments that impacts immune cell phenotypes, population structure, and intercellular communication. However, our understanding of immune phenotypic dynamics in the metastatic niche remains incomplete. Here, we longitudinally assayed lung immune transcriptional profiles in the polyomavirus middle T antigen (PyMT) and 4T1 metastatic breast cancer models from primary tumorigenesis, through pre-metastatic niche formation, to the final stages of metastatic outgrowth at single-cell resolution. Computational analyses of these data revealed a TLR-NFκB inflammatory program enacted by both peripherally derived and tissue-resident myeloid cells that correlated with pre-metastatic niche formation and mirrored CD14+ "activated" myeloid cells in the primary tumor. Moreover, we observed that primary tumor and metastatic niche natural killer (NK) cells are differentially regulated in mice and human patient samples, with the metastatic niche featuring elevated cytotoxic NK cell proportions. Finally, we identified cell-type-specific dynamic regulation of IGF1 and CCL6 signaling during metastatic progression that represents anti-metastatic immunotherapy candidate pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Stanford University, Stanford, CA 94305, USA; Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA 94158, USA; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, US…
- Department of Pathology, Stanford University, Stanford, CA 94305, USA; Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA 94158, USA.
- Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA 94158, USA; Department of Cell and Tissue Biology, UCSF, San Francisco, CA 94143, USA; Department of Medicine, UCSF, San Francisco, CA 94143, USA.
- Department of Otolaryngology, Stanford University, Stanford, CA 94305, USA.
- Center for Cancer Research, Medical University of Vienna, Vienna 1090, Austria. Electronic address: juliane.winkler@meduniwien.ac.at.
Förderung
- NCI NIH HHS
- Congressionally Directed Medical Research Programs
- Parker Institute for Cancer Immunotherapy
- METAvivor
- PEW Charitable Trusts
- US Department of Defense
- KAIST Creative Research Initiatives
- Donald E and Delia B Baxter Foundation
Zitieren
APA
McGinnis, C. S., Miao, Z., Superville, D., Yao, W., Goga, A., Reticker-Flynn, N. E., Winkler, J., & Satpathy, A. T. (2024). The temporal progression of lung immune remodeling during breast cancer metastasis. Cancer Cell, 42(6), 1018-1031.e6. https://doi.org/10.1016/j.ccell.2024.05.004
Vancouver
McGinnis CS, Miao Z, Superville D, Yao W, Goga A, Reticker-Flynn NE, et al. The temporal progression of lung immune remodeling during breast cancer metastasis. Cancer Cell. 2024;42(6):1018-1031.e6. doi:10.1016/j.ccell.2024.05.004
BibTeX
@article{McGinnis2024,
author = {McGinnis, Christopher S and Miao, Zhuang and Superville, Daphne and Yao, Winnie and Goga, Andrei and Reticker-Flynn, Nathan E and Winkler, Juliane and Satpathy, Ansuman T},
title = {The temporal progression of lung immune remodeling during breast cancer metastasis},
journal = {Cancer Cell},
year = {2024},
volume = {42},
number = {6},
pages = {1018--1031.e6},
doi = {10.1016/j.ccell.2024.05.004}
}
EUVIMED